MEDNAX, Inc. is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company's national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications. As of December 31, 2016, the Company had over 1,390 affiliated physicians providing anesthesia care to patients in connection with surgical and other procedures, as well as pain management. As of December 31, 2016, the Company had 270 affiliated physicians providing maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies primarily in areas where its affiliated neonatal physicians practice.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Healthcare Facilities & Services - NEC
- Sub-Industry: Health Care Services
- Symbol: NYSE:MD
- CUSIP: 58502B10
- Web: www.mednax.com
Capitalization:- Market Cap: $5.41 billion
- Outstanding Shares: 93,016,000
Average Prices:- 50 Day Moving Avg: $57.74
- 200 Day Moving Avg: $63.76
- 52 Week Range: $53.80 - $76.04
P/E:- Trailing P/E Ratio: 17.35
- Foreward P/E Ratio: 14.67
- P/E Growth: 1.12
Sales & Book Value:- Annual Revenue: $3.27 billion
- Price / Sales: 1.65
- Book Value: $29.91 per share
- Price / Book: 1.94
Profitability:- EBIDTA: $648.78 million
- Net Margins: 9.54%
- Return on Equity: 12.81%
- Return on Assets: 6.60%
Debt:- Debt-to-Equity Ratio: 0.68%
- Current Ratio: 1.71%
- Quick Ratio: 1.71%
Misc:- Average Volume: 924,517 shs.
- Beta: 0.44
- Short Ratio: 8.38
Frequently Asked Questions for Mednax (NYSE:MD)
What is Mednax's stock symbol?
Mednax trades on the New York Stock Exchange (NYSE) under the ticker symbol "MD."
How were Mednax's earnings last quarter?
Mednax, Inc (NYSE:MD) issued its earnings results on Thursday, May, 4th. The company reported $0.75 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.74 by $0.01. The business earned $835.60 million during the quarter, compared to the consensus estimate of $837.01 million. Mednax had a return on equity of 12.81% and a net margin of 9.54%. The company's revenue for the quarter was up 11.0% on a year-over-year basis. During the same period last year, the company earned $0.87 EPS. View Mednax's Earnings History.
What guidance has Mednax issued on next quarter's earnings?
Mednax updated its second quarter earnings guidance on Thursday, May, 4th. The company provided earnings per share guidance of $0.85-0.89 for the period, compared to the Thomson Reuters consensus estimate of $1.00.
Where is Mednax's stock going? Where will Mednax's stock price be in 2017?
10 brokerages have issued 12-month target prices for Mednax's stock. Their predictions range from $53.00 to $72.00. On average, they anticipate Mednax's share price to reach $64.50 in the next twelve months. View Analyst Ratings for Mednax.
What are analysts saying about Mednax stock?
Here are some recent quotes from research analysts about Mednax stock:
- 1. According to Zacks Investment Research, "Mednax, Inc., formerly Pediatrix Medical Group, Inc. is a healthcare services company that focuses on physician services for newborn, maternal-fetal, pediatric subspecialty and anesthesia care. The company ,through its subsidiaries, provides these services in the United States and Puerto Rico. In addition, MEDNAX engages in clinical research, monitoring clinical outcomes, and implementing clinical initiatives. " (4/27/2017)
- 2. Jefferies Group LLC analysts commented, "Following MD's 5% EPS miss in Q4, we believe our Hold thesis from our December downgrade still holds and would expect the stock to give up some of its premium valuation pending improved earnings visibility. Broader birth trends remain subdued, MD faces its toughest comp of the year in Q1-17, and the company's deal flow remains relatively moderate, leading us to believe that the achievability of Q1 guidance (following 3 consecutive EPS misses) remains uncertain." (2/8/2017)
Who are some of Mednax's key competitors?
Some companies that are related to Mednax include NMC Health PLC (NMC), Acadia Healthcare Company (ACHC), HealthSouth Corporation (HLS), Molina Healthcare (MOH), Chemed Corp. (CHE), LifePoint Health (LPNT), Select Medical Holdings Corporation (SEM), Udg Healthcare PLC (UDG), Tenet Healthcare Corporation (THC), HMS Holdings Corp (HMSY), Community Health Systems (CYH), Kindred Healthcare (KND), HealthStream (HSTM), China Cord Blood Corporation (CO), American Renal Associates Holdings (ARA), Georgia Healthcare Group PLC (GHG), Cambian Group PLC (CMBN) and Concord Medical Services Holdings Limited (CCM).
Who are Mednax's key executives?
Mednax's management team includes the folowing people:
- Cesar L. Alvarez, Chairman of the Board
- Joseph M. Calabro, President, Chief Operating Officer
- Roger J. Medel M.D., Chief Executive Officer, Director
- Vivian Lopez-Blanco, Chief Financial Officer, Treasurer
- David A. Clark, President - MEDNAX National Medical Group Division
- John C. Pepia, Senior Vice President, Chief Accounting Officer
- Dominic J. Andreano, Senior Vice President, General Counsel, Secretary
- Manuel Kadre, Lead Independent Director
- Karey D. Barker, Independent Director
- Waldemar A. Carlo M.D., Independent Director
Who owns Mednax stock?
Mednax's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Fenimore Asset Management Inc. (0.94%), Hermes Investment Management Ltd. (0.68%), Handelsbanken Fonder AB (0.22%), BB&T Corp (0.16%), BTIM Corp. (0.10%) and Handelsinvest Investeringsforvaltning (0.08%). Company insiders that own Mednax stock include Cesar L Alvarez, Dominic J Andreano, Enrique Sosa, John C Pepia, Joseph M Calabro, Karl B Wagner, Manuel Kadre, Md Carlo A Waldemar, Md Pascal J Goldschmidt, Michael D Stanley, Paul G Gabos, Roger Md Medel and Vivian Lopez-Blanco. View Institutional Ownership Trends for Mednax.
Who sold Mednax stock? Who is selling Mednax stock?
Mednax's stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Hermes Investment Management Ltd., Handelsbanken Fonder AB, APG Asset Management N.V., US Bancorp DE, Profit Investment Management LLC, Aperio Group LLC and Integrated Investment Consultants LLC. Company insiders that have sold Mednax stock in the last year include Dominic J Andreano, Enrique Sosa, John C Pepia, Joseph M Calabro, Md Carlo A Waldemar, Md Pascal J Goldschmidt, Paul G Gabos and Vivian Lopez-Blanco. View Insider Buying and Selling for Mednax.
Who bought Mednax stock? Who is buying Mednax stock?
Mednax's stock was acquired by a variety of institutional investors in the last quarter, including Handelsinvest Investeringsforvaltning, Fenimore Asset Management Inc., Mn Services Vermogensbeheer B.V., BB&T Corp, BTIM Corp., NN Investment Partners Holdings N.V., Oregon Public Employees Retirement Fund and LS Investment Advisors LLC. Company insiders that have bought Mednax stock in the last two years include Manuel Kadre and Md Pascal J Goldschmidt. View Insider Buying and Selling for Mednax.
How do I buy Mednax stock?
Shares of Mednax can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Mednax's stock price today?
One share of Mednax stock can currently be purchased for approximately $58.11.
MarketBeat Community Rating for Mednax (NYSE MD)MarketBeat's community ratings are surveys of what our community members think about Mednax and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Mednax (NYSE:MD) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Sell Rating, 8 Hold Ratings, 1 Buy Rating |
| Consensus Rating: | Hold (Score: 2.00) |
| Consensus Price Target: | $64.50 (11.00% upside) |
Analysts' Ratings History for Mednax (NYSE:MD)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/6/2017 | Jefferies Group LLC | Reiterated Rating | Hold | $50.00 -> $53.00 | Medium |  |
| 6/22/2017 | Stephens | Upgrade | Equal Weight -> Overweight | $55.00 -> $68.00 | High | |
| 5/30/2017 | Mizuho | Lower Price Target | Neutral -> Neutral | $64.00 -> $58.00 | Low | |
| 5/25/2017 | Stifel Nicolaus | Lower Price Target | Hold | $65.00 -> $58.00 | Low | |
| 5/4/2017 | Bank of America Corporation | Downgrade | Buy -> Underperform | | Low | |
| 3/21/2017 | Robert W. Baird | Downgrade | Outperform -> Neutral | $72.00 | High | |
| 3/10/2017 | J P Morgan Chase & Co | Reiterated Rating | Overweight -> Neutral | $69.00 | Low | |
| 12/9/2016 | Goldman Sachs Group, Inc. (The) | Initiated Coverage | Neutral | $66.00 | N/A | |
| 10/27/2016 | Raymond James Financial, Inc. | Downgrade | Outperform -> Market Perform | | N/A | |
| 8/17/2016 | Citigroup Inc. | Lower Price Target | Neutral | $76.00 -> $72.00 | N/A | |
| 3/14/2016 | Piper Jaffray Companies | Reiterated Rating | Overweight | $76.00 | N/A | |
| 3/7/2016 | Susquehanna Bancshares Inc | Downgrade | Positive -> Neutral | $94.00 -> $70.00 | N/A | |
| 9/20/2015 | William Blair | Reiterated Rating | Buy | | N/A | |
| 7/31/2015 | Dougherty & Co | Boost Price Target | Buy | $88.00 -> $90.00 | N/A | |
(Data available from 7/23/2015 forward)
Earnings History for Mednax (NYSE:MD)Earnings History by Quarter for Mednax (NYSE MD)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/4/2017 | Q1 2017 | $0.74 | $0.75 | $837.01 million | $835.60 million | View | N/A | |
| 2/7/2017 | Q416 | $1.06 | $1.00 | $842.15 million | $831.00 million | View | Listen | |
| 10/27/2016 | Q316 | $1.05 | $1.09 | $821.18 million | $828.00 million | View | Listen | |
| 7/28/2016 | Q216 | $1.07 | $1.03 | $775.68 million | $772.00 million | View | Listen | |
| 4/28/2016 | Q116 | $0.86 | $0.87 | $741.49 million | $752.60 million | View | Listen | |
| 2/4/2016 | Q415 | $1.10 | $1.13 | $748.02 million | $742.00 million | View | Listen | |
| 10/29/2015 | Q315 | $0.97 | $1.10 | $730.63 million | $722.30 million | View | Listen | |
| 7/30/2015 | Q215 | $0.88 | $0.97 | $677.02 million | $676.60 million | View | Listen | |
| 4/30/2015 | Q115 | $0.71 | $0.72 | $641.24 million | $639.40 million | View | Listen | |
| 1/29/2015 | Q414 | $0.87 | $0.89 | $637.90 million | $651.00 million | View | Listen | |
| 10/30/2014 | Q314 | $0.85 | $0.86 | $619.61 million | $627.00 million | View | Listen | |
| 7/31/2014 | Q214 | $0.78 | $0.79 | $603.00 million | $595.54 million | View | Listen | |
| 5/1/2014 | Q114 | $0.63 | $0.63 | $574.80 million | $566.00 million | View | Listen | |
| 1/30/2014 | Q4 | $0.75 | $0.20 | $555.30 million | $567.00 million | View | Listen | |
| 10/31/2013 | Q313 | $1.48 | $1.52 | $556.63 million | $555.00 million | View | Listen | |
| 7/30/2013 | Q2 2013 | $1.36 | $1.37 | $533.39 million | $529.18 million | View | Listen | |
| 5/2/2013 | Q1 2013 | $1.09 | $1.10 | $504.24 million | $502.70 million | View | Listen | |
| 1/31/2013 | Q4 2012 | $1.30 | $1.32 | $473.70 million | $471.30 million | View | Listen | |
| 11/1/2012 | Q312 | $1.28 | $1.32 | $470.60 million | $473.10 million | View | N/A | |
| 7/31/2012 | | $1.19 | $1.22 | | | View | N/A | |
| 5/3/2012 | | $1.00 | $0.98 | | | View | N/A | |
| 2/2/2012 | | $1.19 | $1.19 | | | View | N/A | |
| 11/1/2011 | | $1.18 | $1.19 | | | View | N/A | |
| 8/2/2011 | | $1.15 | $1.15 | | | View | N/A | |
| 5/3/2011 | | $0.91 | $0.94 | | | View | N/A | |
| 2/3/2011 | | $1.12 | $1.12 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Mednax (NYSE:MD)2017 EPS Consensus Estimate: $3.86
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 3 | $0.80 | $0.81 | $0.81 |
| Q2 2017 | 2 | $0.99 | $1.00 | $1.00 |
| Q3 2017 | 3 | $0.90 | $1.09 | $1.02 |
| Q4 2017 | 3 | $0.94 | $1.09 | $1.03 |
(Data provided by Zacks Investment Research)
Dividend History for Mednax (NYSE:MD)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Mednax (NYSE:MD)Insider Ownership Percentage: 2.40%
Insider Trades by Quarter for Mednax (NYSE:MD)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 6/14/2017 | Md Pascal J Goldschmidt | Director | Sell | 1,969 | $57.57 | $113,355.33 | |
| 6/1/2017 | Joseph M Calabro | Insider | Sell | 23,327 | $55.00 | $1,282,985.00 | |
| 5/5/2017 | Manuel Kadre | Director | Buy | 21,704 | $55.79 | $1,210,866.16 | |
| 5/5/2017 | Vivian Lopez-Blanco | CFO | Sell | 7,778 | $55.82 | $434,167.96 | |
| 2/23/2017 | Enrique Sosa | Director | Sell | 10,668 | $69.65 | $743,026.20 | |
| 2/17/2017 | Vivian Lopez-Blanco | CFO | Sell | 15,164 | $70.01 | $1,061,631.64 | |
| 2/16/2017 | Dominic J Andreano | SVP | Sell | 6,000 | $69.59 | $417,540.00 | |
| 2/16/2017 | John C Pepia | Insider | Sell | 2,500 | $69.58 | $173,950.00 | |
| 2/16/2017 | Paul G Gabos | Director | Sell | 21,336 | $69.63 | $1,485,625.68 | |
| 2/10/2017 | Md Pascal J Goldschmidt | Director | Sell | 25,294 | $67.82 | $1,715,439.08 | |
| 2/9/2017 | Md Carlo A Waldemar | Director | Sell | 5,334 | $67.90 | $362,178.60 | |
| 1/17/2017 | Vivian Lopez-Blanco | CFO | Sell | 10,000 | $70.95 | $709,500.00 | |
| 12/7/2016 | Md Pascal J Goldschmidt | Director | Buy | 2,100 | $66.52 | $139,692.00 | |
| 9/14/2016 | Md Pascal J Goldschmidt | Director | Sell | 1,500 | $65.01 | $97,515.00 | |
| 6/13/2016 | Dominic J Andreano | SVP | Sell | 3,922 | $68.80 | $269,833.60 | |
| 6/8/2016 | Md Carlo A Waldemar | Director | Sell | 5,334 | $70.50 | $376,047.00 | |
| 6/7/2016 | Karl B Wagner | Insider | Sell | 27,482 | $68.45 | $1,881,142.90 | |
| 6/1/2016 | Joseph M Calabro | COO | Sell | 28,347 | $67.78 | $1,921,359.66 | |
| 6/1/2016 | Michael D Stanley | Insider | Sell | 14,778 | $67.78 | $1,001,652.84 | |
| 5/16/2016 | Dominic J Andreano | SVP | Sell | 3,000 | $68.53 | $205,590.00 | |
| 5/2/2016 | Vivian Lopez-Blanco | CFO | Sell | 9,350 | $71.22 | $665,907.00 | |
| 3/11/2016 | Md Pascal J Goldschmidt | Director | Sell | 3,100 | $65.00 | $201,500.00 | |
| 2/29/2016 | Paul G Gabos | Director | Sell | 10,668 | $67.15 | $716,356.20 | |
| 12/11/2015 | Md Pascal J. Goldschmidt | Director | Sell | 5,250 | $70.99 | $372,697.50 | |
| 9/8/2015 | Cesar L. Alvarez | Director | Sell | 10,668 | $81.00 | $864,108.00 | |
| 8/27/2015 | Roger Md Medel | CEO | Sell | 100,000 | $80.27 | $8,027,000.00 | |
| 6/8/2015 | Karl B Wagner | Insider | Sell | 37,820 | $70.28 | $2,657,989.60 | |
| 6/3/2015 | Joseph M Calabro | COO | Sell | 108,071 | $70.51 | $7,620,086.21 | |
| 3/9/2015 | Md Pascal J Goldschmidt | Director | Sell | 8,500 | $71.25 | $605,625.00 | |
| 2/26/2015 | Roger Md Medel | CEO | Sell | 100,000 | $71.61 | $7,161,000.00 | |
| 2/20/2015 | Md Carlo A Waldemar | Director | Sell | 10,668 | $71.50 | $762,762.00 | |
| 2/6/2015 | Dominic J Andreano | SVP | Sell | 3,200 | $70.75 | $226,400.00 | |
| 2/6/2015 | Vivian Lopez-Blanco | CFO | Sell | 8,250 | $69.95 | $577,087.50 | |
| 2/2/2015 | Paul G Gabos | Director | Sell | 17,584 | $68.07 | $1,196,942.88 | |
| 1/30/2015 | William C Hawk | COO | Sell | 3,598 | $68.50 | $246,463.00 | |
| 11/14/2014 | Roger Md Medel | CEO | Sell | 51,290 | $62.59 | $3,210,241.10 | |
| 11/13/2014 | Roger Md Medel | CEO | Sell | 63,440 | $62.55 | $3,968,172.00 | |
| 11/7/2014 | Roger Md Medel | CEO | Sell | 128,833 | $62.60 | $8,064,945.80 | |
| 11/5/2014 | Roger Md Medel | CEO | Sell | 169,845 | $62.60 | $10,632,297.00 | |
| 11/4/2014 | Roger Md Medel | CEO | Sell | 15,052 | $62.52 | $941,051.04 | |
| 11/3/2014 | Roger Md Medel | CEO | Sell | 10,881 | $62.52 | $680,280.12 | |
| 10/31/2014 | Roger Md Medel | CEO | Sell | 61,592 | $62.58 | $3,854,427.36 | |
| 10/30/2014 | Karl B Wagner | Insider | Sell | 40,000 | $62.50 | $2,500,000.00 | |
| 10/30/2014 | Vivian Lopez-Blanco | CFO | Sell | 8,800 | $60.00 | $528,000.00 | |
| 7/30/2014 | Karl B Wagner | Insider | Sell | 80,000 | $60.00 | $4,800,000.00 | |
| 6/10/2014 | Dominic J Andreano | SVP | Sell | 2,252 | $58.48 | $131,696.96 | |
| 6/6/2014 | Karl B Wagner | Insider | Sell | 44,596 | $58.53 | $2,610,203.88 | |
| 6/5/2014 | William C Hawk | COO | Sell | 6,911 | $57.66 | $398,488.26 | |
| 6/2/2014 | David A Clark | COO | Sell | 16,230 | $57.00 | $925,110.00 | |
| 6/2/2014 | Michael D Stanley | Insider | Sell | 18,006 | $57.00 | $1,026,342.00 | |
| 5/9/2014 | Karl Wagner | Insider | Sell | 79,524 | $57.09 | $4,540,025.16 | |
| 5/9/2014 | Md Pascal Goldschmidt | Director | Sell | 30,000 | $57.11 | $1,713,300.00 | |
| 5/8/2014 | Joseph Calabro | COO | Sell | 137,500 | $57.06 | $7,845,750.00 | |
| 2/20/2014 | Dominic Andreano | SVP | Sell | 3,000 | $61.00 | $183,000.00 | |
| 2/10/2014 | Joseph Calabro | COO | Sell | 150,000 | $55.55 | $8,332,500.00 | |
| 2/10/2014 | Md Carlo Waldemar | Director | Sell | 10,668 | $55.40 | $591,007.20 | |
| 11/7/2013 | Enrique Sosa | Director | Sell | 5,334 | $107.00 | $570,738.00 | |
| 11/7/2013 | Karl Wagner | Insider | Sell | 1,800 | $107.60 | $193,680.00 | |
| 9/11/2013 | William C Hawk | COO | Sell | 3,162 | $100.62 | $318,160.44 | |
| 9/10/2013 | Dominic J Andreano | SVP | Sell | 3,718 | $99.63 | $370,424.34 | |
| 8/7/2013 | Karl Wagner | Insider | Sell | 25,000 | $98.01 | $2,450,250.00 | |
| 8/2/2013 | Joseph M Calabro | COO | Sell | 36,154 | $98.57 | $3,563,699.78 | |
| 6/3/2013 | David A Clark | COO | Sell | 8,645 | $91.01 | $786,781.45 | |
| 6/3/2013 | Michael D Stanley | Insider | Sell | 8,906 | $91.01 | $810,535.06 | |
(Data available from 1/1/2013 forward)
Headline Trends for Mednax (NYSE:MD)
Latest Headlines for Mednax (NYSE:MD)
| Source: |
|
| Date | Headline |
|---|
 | $851.11 Million in Sales Expected for Mednax, Inc (NYSE:MD) This Quarter
www.americanbankingnews.com - July 21 at 7:35 PM |
 | MEDNAX, Inc. breached its 50 day moving average in a Bearish Manner : MD-US : July 20, 2017
finance.yahoo.com - July 21 at 2:10 AM |
| MEDNAX 2017 Second Quarter Conference Call/Webcast Scheduled for Friday, July 28, 2017
finance.yahoo.com - July 18 at 11:14 PM |
| Mednax, Inc (MD) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - July 17 at 2:50 PM |
| ETFs with exposure to MEDNAX, Inc. : July 14, 2017
finance.yahoo.com - July 15 at 6:21 AM |
| MEDNAX Radiology and vRad to Exhibit at AHRA 2017 Annual Meeting
finance.yahoo.com - July 11 at 1:27 AM |
| Mednax, Inc (NYSE:MD) Given "Hold" Rating at Jefferies Group LLC
www.americanbankingnews.com - July 9 at 7:22 AM |
| Q3 2017 Earnings Forecast for Mednax, Inc (NYSE:MD) Issued By Jefferies Group
www.americanbankingnews.com - July 7 at 10:53 AM |
| ETFs with exposure to MEDNAX, Inc. : July 4, 2017
finance.yahoo.com - July 4 at 6:43 PM |
| Analysts Anticipate Mednax, Inc (MD) Will Post Quarterly Sales of $850.54 Million
www.americanbankingnews.com - June 25 at 1:02 PM |
| Mednax, Inc (MD) Upgraded to Overweight at Stephens
www.americanbankingnews.com - June 25 at 7:11 AM |
| Mednax, Inc (MD) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - June 23 at 7:38 PM |
| Zacks: Analysts Expect Mednax, Inc (MD) to Announce $0.81 Earnings Per Share
www.americanbankingnews.com - June 23 at 11:32 AM |
 | Mednax, Inc. Reaches Analyst Target Price
www.nasdaq.com - June 22 at 8:44 AM |
| MEDNAX, Inc. breached its 50 day moving average in a Bullish Manner : MD-US : June 22, 2017
finance.yahoo.com - June 22 at 8:44 AM |
| MEDNAX Announces Acquisition of Maternal-Fetal Medicine Practice in Tennessee
finance.yahoo.com - June 20 at 7:28 PM |
| MEDNAX Inc (MD) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - June 20 at 3:04 PM |
| ETFs with exposure to MEDNAX, Inc. : June 19, 2017
finance.yahoo.com - June 19 at 5:32 PM |
| MEDNAX, Inc. :MD-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017
finance.yahoo.com - June 16 at 7:24 PM |
| Snap Has Shed an Astounding $13 Billion in Value and Now the Stock Is Trading Near Its IPO Price
finance.yahoo.com - June 16 at 7:40 AM |
 | MEDNAX (MD) Presents At The William Blair 2017 Growth Stock Conference - Slideshow
seekingalpha.com - June 14 at 9:47 PM |
| Mednax, Inc (MD) Director Md Pascal J. Goldschmidt Sells 1,969 Shares
www.americanbankingnews.com - June 14 at 8:19 PM |
 | 4 Reasons to Stay Away from Mednax Now
www.benzinga.com - June 8 at 10:27 AM |
| 4 Reasons to Stay Away from Mednax (MD) Now
finance.yahoo.com - June 7 at 6:06 PM |
| AMN Healthcare Services (AMN) and MEDNAX (MD) Head-To-Head Survey
www.americanbankingnews.com - June 6 at 8:44 AM |
| MEDNAX Inc (MD) Lowered to Hold at ValuEngine
www.americanbankingnews.com - June 4 at 8:06 AM |
| A Deep Analysis of 6 Five-Star Companies
finance.yahoo.com - June 3 at 8:09 AM |
| MEDNAX Inc (MD) Insider Joseph M. Calabro Sells 23,327 Shares
www.americanbankingnews.com - June 2 at 7:42 PM |
| What Makes MEDNAX (MD) a Strong Sell?
finance.yahoo.com - May 31 at 6:51 PM |
| MEDNAX Inc (MD) Expected to Post Quarterly Sales of $850.54 Million
www.americanbankingnews.com - May 31 at 11:10 AM |
| MEDNAX Inc (MD) PT Lowered to $58.00
www.americanbankingnews.com - May 30 at 7:24 AM |
| MEDNAX Inc (MD) Expected to Announce Earnings of $0.81 Per Share
www.americanbankingnews.com - May 29 at 10:26 PM |
| Oversold Conditions For Mednax (MD)
www.nasdaq.com - May 26 at 7:16 PM |
| MEDNAX Inc (MD) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - May 26 at 2:52 PM |
| MEDNAX Inc (MD) Price Target Cut to $58.00 by Analysts at Stifel Nicolaus
www.americanbankingnews.com - May 25 at 10:41 AM |
| MEDNAX Inc (MD) Downgraded to "C+" at TheStreet
www.americanbankingnews.com - May 19 at 1:38 PM |
| Short Interest in MEDNAX Inc (MD) Drops By 24.9%
www.americanbankingnews.com - May 16 at 7:14 AM |
| Insider Selling: MEDNAX Inc (MD) CFO Sells 7,778 Shares of Stock
www.americanbankingnews.com - May 8 at 7:36 PM |
| MEDNAX Inc (MD) Director Buys $1,210,866.16 in Stock
www.americanbankingnews.com - May 8 at 7:17 PM |
| MEDNAX Inc (MD) Expected to Post Quarterly Sales of $859.84 Million
www.americanbankingnews.com - May 6 at 9:53 AM |
| MEDNAX (MD) Receives Daily Media Sentiment Score of 0.07
www.americanbankingnews.com - May 5 at 11:45 PM |
| Edited Transcript of MD earnings conference call or presentation 4-May-17 2:00pm GMT
finance.yahoo.com - May 4 at 11:34 PM |
| MEDNAX Inc (MD) Rating Lowered to Underperform at Bank of America Corp
www.americanbankingnews.com - May 4 at 10:56 PM |
| MEDNAX Inc (MD) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - May 4 at 9:48 PM |
| MEDNAX Inc (MD) Issues Q2 Earnings Guidance
www.americanbankingnews.com - May 4 at 12:04 PM |
| MEDNAX Reports First Quarter GAAP EPS of $0.59; Adjusted EPS of $0.75
finance.yahoo.com - May 4 at 11:45 AM |
| MEDNAX Inc (MD) Expected to Post Earnings of $0.99 Per Share
www.americanbankingnews.com - May 4 at 7:46 AM |
| Mednax misses by $0.13, misses on revenue
seekingalpha.com - May 4 at 6:07 AM |
 | Specialized Health Services Stocks on Investors' Radar -- DaVita, Acadia Healthcare, HealthSouth, and MEDNAX
www.bizjournals.com - May 3 at 5:33 PM |
| MEDNAX (MD) Receives Coverage Optimism Score of 0.11
www.americanbankingnews.com - May 2 at 5:04 PM |
Mednax (MD) Chart for Sunday, July, 23, 2017
